June 23, 2008 - Dainippon Sumitomo Pharma Co., Ltd. launches AVAPRO® tablet 50 mg / 100 mg, anti-hypertension drug (generic name: irbesartan) as of July 1, 2008.
AVAPRO® is a long-acting ARB (angiotensin II receptor antagonist) with a long half-life in blood and a 24-hour-lasting blood pressure-lowering effect, having high anti-hypertensive effect in mild to severe hypertension.
Irbesartan was discovered by sanofi-aventis , co-developed by sanofi-aventis and Bristol Myers Squibb and was launched in 1997 overseas. This drug is currently sold in 86 countries under the brand name of AVAPRO and APROVEL. Based on the large-scale clinical trials, IDNT and IRMA2, which are often cited in the major international guidelines, this drug is also recognized as the only one ARB with evidence for its renoprotective effect in hypertensive type 2 diabetic patients covering both early-stage and overt nephropathy at 300mg/day, and is highly regarded as one of the top ARB brands.
No comments:
Post a Comment